This business information is not released now.


Back
This page is displayed by "Spiral" of PIPED BITS Co.,Ltd., which is a database management ASP service, our contracted partner.


Rena Therapeutics Inc.
【Field/Business】
Pharmaceutical/Drug Discovery


last update:2017/9/14
Profile

Delegates :
Jun Sasaki


Incorporated :
January  15 , 2015

Paid in Capital :
629 Million yen  

Employees :
14 人

Address :
Global Business Hub Tokyo, Otemachi Financial City Grand Cube 3F 9-2, Otemachi 1-chome, Chiyoda-ku, TOKYO
〒100-0004

TEL/FAX :
+81-3-4243-6081 / +81-3-4243-6097

URL:
http://www.renatherapeutics.com/index.html

Attachment :

Mission/Background :
Rena Therapeutics is a Tokyo based DDS platform provider for Nucleic Acid Medicine.
Our technology, Hetero-Duplex Oligonucleotide Technology, is new generation platform of nucleic acid medicine, which realizes targeting delivery by its unique structure.

Technology & Business
Hetero-Duplex Oligonucleotide (HDO) Technology can be applicable to your drug assets (your target genes, DDS ligands etc.) and maximize your assets business potential.

Advantages of HDO technology is as below:
- Delivery
Realize specific targeting by conjugated various delivery molecules to complimentary sense strand (lower strand, as illustrated above) without modification on antisense antisense strands
- Efficacy
Realize very high knockdown efficacy (over 20x knock-down effect compared to ASO)
- Applicability
HDO Technology can be applied to any ASO in development, target genes and delivery ligands in your drug assets.
Products & Service
Products & Service Name
Stage
Outline
Milestone
Hetero-Duplex Olgonucleotide
Discovery
Platform technology for nucleic acid medicine drug discovery and development
Drug development alliance with pharmaceutical companies
















Highlights
In the approximately 2 years since the establishment of our company, we have already concluded joint research agreements with two pharmaceutical companies and are conducting joint research and development of nucleic acid medicine. In addition, we have concluded confidentiality agreements with about 10 companies and are exchanging information with them.
Hot news

Alliance strategy
Our company provides the HDO technology as a drug development platform of nucleic acid medicine to pharmaceutical companies. Also, we grant exclusive license of the HDO technology related patents gene by gene basis.

 
This page is displayed by "Spiral" of PIPED BITS Co.,Ltd., which is a database management ASP service, our contracted partner.